- Home
- IMVT vs MAC Comparison
IMVT vs MAC Comparison
Compare IMVT & MAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMVT | MAC |
|---|---|---|
| Founded | 2018 | 1964 |
| Country | United States | United States |
| Employees | N/A | 2845 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.9B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | IMVT | MAC |
|---|---|---|
| Price | $28.57 | $22.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $33.00 | $20.50 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | N/A | ★ 11.36 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,013,983,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.43 |
| 52 Week Low | $13.52 | $14.82 |
| 52 Week High | $30.09 | $22.56 |
Technical Indicators
Market Signals| Indicator | IMVT | MAC |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 65.16 |
| Support Level | $22.25 | $17.84 |
| Resistance Level | $29.67 | $22.56 |
| Average True Range (ATR) | 1.28 | 0.51 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 63.57 | 69.35 |
Price Performance
Historical ComparisonAbout IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.